Quantcast
Last updated on April 24, 2014 at 21:24 EDT

Latest Sosei Co. Ltd. Stories

2013-03-12 04:21:10

TOKYO, March 12, 2013 /PRNewswire/ -- Sosei Group Corporation (TSE Mothers Index: 4565), the biopharmaceutical company, today announces that its Japanese subsidiary, Sosei Co., Ltd., has initiated a Phase III trial for SO-1105 for the treatment of oropharyngeal candidiasis. The study is an open-label, randomised, multiple centres, parallel-group design (with open active comparator miconazole gel), and will assess efficacy and safety of SO-1105. SO-1105 is an...

2012-07-01 22:20:50

TOKYO, July 2, 2012 /PRNewswire/ -- Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565), the biopharmaceutical company, today announces that its wholly owned Japanese subsidiary, Sosei Co., Ltd., has successfully completed a Japanese Phase I trial for SO-1105 for the treatment of oropharyngeal candidiasis. SO-1105 was originally developed by a French pharmaceutical company, BioAlliance Pharma, which received its first marketing authorization for SO-1105 in France in...

2012-03-08 00:30:00

TOKYO, March 8, 2012 /PRNewswire/ -- Sosei Group Corporation ("Sosei". TSE Mothers Index: 4565), announces that the board of its fully-owned subsidiary, Sosei Co., Ltd resolved to enter into an agreement with JAFCO Super V3, a general partnership investment fund owned by JAFCO Co., Ltd, for a non-brokered private placement of preferred shares of Sosei Co., Ltd, for gross proceeds of up to 836 million yen. About the Private Placement The additional funds raised...

2012-03-08 00:30:00

TOKYO, March 8, 2012 /PRNewswire/ -- Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565), the biopharmaceutical company, today announces that its wholly owned Japanese subsidiary, Sosei Co., Ltd., has initiated a Japanese Phase I trial for SO-1105 for the treatment of oropharyngeal candidiasis. SO-1105 was originally developed by a French pharmaceutical company, BioAlliance Pharma, which received its first marketing authorization for SO-1105 in France in October 2006....

2011-05-23 01:00:00

TOKYO, May 23, 2011 /PRNewswire-FirstCall/ -- Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565), the biopharmaceutical company, today announced that Sosei Co., Ltd., its wholly owned Japanese subsidiary, will launch its emergency contraceptive pill, NorLevo(R) TABLETS 0.75mg, tomorrow 24 May, through the distribution network of its commercialization partner, ASKA Pharmaceutical Co., Ltd. NorLevo(R) is an oral emergency contraceptive, which is taken within 72 hours after...

2011-05-11 01:00:00

TOKYO, May 11, 2011 /PRNewswire-FirstCall/ -- Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565), the biopharmaceutical company, today announces that Sosei Co., Ltd., its wholly owned Japanese subsidiary, acquired development and commercialization rights to Loramyc(R) (miconazole Lauriad(R). Sosei development code: SO-1105) in Japan from BioAlliance Pharma. Loramyc(R) is an antifungal agent, administered as a muco-adhesive buccal tablet for the treatment of oropharyngeal...

2011-02-23 00:29:00

TOKYO, Japan, February 23, 2011 /PRNewswire-FirstCall/ -- Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565), the biopharmaceutical company, today announced that Sosei Co., Ltd., its wholly owned Japanese subsidiary, was granted approval for its emergency contraceptive pill, NorLevo(R) TABLETS 0.75mg, by the Japan Ministry of Health, Labour and Welfare (MHLW). NorLevo(R) has thus become the fist emergency contraceptive pill available in Japan. NorLevo(R) is an oral emergency...

2009-11-02 00:30:00

TOKYO, November 2 /PRNewswire-FirstCall/ -- Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565), the biopharmaceutical company, today announced that Sosei Co., Ltd., its wholly owned Japanese subsidiary, has entered into a definitive distribution agreement with ASKA Pharmaceuticals Co., Ltd. ("ASKA", TSE First Section Index: 4514) for the commercialisation of the emergency contraceptive pill SOH-075 (NorLevo(R)). NorLevo(R) is an oral emergency contraceptive "morning after...

2009-09-30 01:30:00

TOKYO, September 30 /PRNewswire-FirstCall/ -- Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565), the biopharmaceutical company, today announced the submission of the New Drug Application (NDA) for the emergency contraceptive pill SOH-075 (NorLevo(R)) to Ministry of Health, Labour and Welfare (MHLW) by Sosei Co. Ltd., its wholly owned Japanese subsidiary. NorLevo(R) is an oral emergency contraceptive "morning after pill" which is used to prevent unwanted pregnancy after...

2008-12-08 00:30:00

TOKYO, December 8 /PRNewswire-FirstCall/ -- Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565), a biopharmaceutical company, today announces the successful results of two Phase I trials for its collaborative project on SD118, a compound in development for the treatment of neuropathic pain. SD118 is being jointly developed with NeuroDiscovery Ltd (ASX Code: NDL) and its wholly owned subsidiary NeuroSolutions Ltd under a Collaboration Agreement concluded in June 2006. SD118 was...